Past, present, and future challenges in breast cancer treatment.
about
Optimal management of hormone receptor positive metastatic breast cancer in 2016Targeting Breast Cancer MetastasisBreast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled TrialsAnnual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival.National Trends in the Use of Neoadjuvant Chemotherapy for Hormone Receptor-Negative Breast Cancer: A National Cancer Data Base Study.Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.Neuropilin-1 Associated Molecules in the Blood Distinguish Poor Prognosis Breast Cancer: A Cross-Sectional Study.Anti-cancerous effect of albumin coated silver nanoparticles on MDA-MB 231 human breast cancer cell line.A therapeutic microparticle-based tumor lysate vaccine reduces spontaneous metastases in murine breast cancer.The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer.Breast cancer survival experiences at a tertiary hospital in sub-Saharan Africa: a cohort study.Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic ImagingThe molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy.Surgical Options and Locoregional Recurrence in Patients Diagnosed with Invasive Lobular Carcinoma of the BreastAECHL-1 targets breast cancer progression via inhibition of metastasis, prevention of EMT and suppression of Cancer Stem Cell characteristics.The Effect of Treatment Advances on the Mortality Results of Breast Cancer Screening Trials: A Microsimulation Model.Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.FSIP1 binds HER2 directly to regulate breast cancer growth and invasiveness.MicroRNA-7 suppresses the homing and migration potential of human endothelial cells to highly metastatic human breast cancer cells.Metastatic triple-negative breast cancer is dependent on SphKs/S1P signaling for growth and survival.Longitudinal optical monitoring of blood flow in breast tumors during neoadjuvant chemotherapy.Inhibition of Glut1 by WZB117 sensitizes radioresistant breast cancer cells to irradiation.Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis.Breast cancer treatment-induced cardiotoxicity.The American Cancer Society challenge goal to reduce US cancer mortality by 50% between 1990 and 2015: Results and reflections.Modeling estrogen receptor-positive breast cancers in mice: is it the best we can do?Secretory leukocyte protease inhibitor (SLPI) as a potential target for inhibiting metastasis of triple-negative breast cancers.A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers.Extended Adjuvant Aromatase Inhibitor Therapy in Post-Menopausal Women.A Raloxifene Withdrawal Response: Translational Research, Definitions, and Clinical Applications.Anti-proliferative and cytotoxic activities of Allium autumnale P. H. Davis (Amaryllidaceae) on human breast cancer cell lines MCF-7 and MDA-MB-231.Harnessing the immune system in the battle against breast cancer.Opportunities and challenges of long term anti-estrogenic adjuvant therapy: treatment forever or intermittently?Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin.Interleukin 7-expressing fibroblasts promote breast cancer growth through sustenance of tumor cell stemness.Functional miRNAs in breast cancer drug resistance.Recent Advances in the Treatment of Breast Cancer.High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review.The musculoskeletal consequences of latissmus dorsi breast reconstruction in women following mastectomy for breast cancerLong Non-Coding RNAs as New Master Regulators of Resistance to Systemic Treatments in Breast Cancer
P2860
Q26777683-C5992894-F9F0-404A-A543-DBB8B35652BFQ26783925-E2D65B86-AB69-4EBC-97AE-A9E79159DE2BQ28269986-EAB0D2AC-2AD2-4766-8F42-69C0B668E9CCQ30847275-2A0BBD2D-0375-4DA0-B80C-4779B93C611AQ31150366-B03FED90-E815-46BA-BC03-B97A51470B41Q33665716-123C466D-BD61-46E0-8717-084F6687445DQ33789563-5B24A6C5-7524-4F50-9A2A-CDB8B2230F3AQ33899649-C5257C53-9046-4DF0-9080-2FBAD22C2AB1Q35318315-A73E31B1-E9AD-4A00-8C8C-3A7B2396D534Q35827822-87916E98-D609-497C-8589-27588A52A859Q35863808-9FC79B77-B27D-4999-B5D5-9E9E7A234E4BQ36104503-1C8F38E1-4133-4004-AA5E-2BB39F41F538Q36598699-F5992A02-ECEE-4956-812E-32C6A9227A61Q36711189-735977B1-9F1D-4F5F-A4F7-2CF3E82DF3FCQ37504407-1DDE82D1-371C-4BB1-8426-C7D297292C01Q37708613-7098C43B-09EB-4DBC-981F-F1877CBD0FD1Q38375607-8E264698-E66C-4014-B965-E80EDB3EE685Q38431717-E0A18ED9-B603-4A7F-A584-9D2EE22B2AF7Q38701611-09041FF6-8DD6-44A6-8B1B-DF060B9FDF9BQ38720294-5FF15649-A87B-44C4-8561-97AD1781219EQ38731390-A80684C5-8F45-4851-AC77-49686B3B2998Q38783426-E3C79108-1EAF-4D02-A102-8BCD3042D462Q38821290-D36EE9B7-0661-469A-831D-A0130F7AE021Q39428826-2D9D1BB0-EAEE-458A-9047-5E073A8F41A1Q40756146-F6E92584-9304-47AE-B29D-4B0EBED704E5Q42701994-D0AAAC91-5864-4EC2-8439-3955375663AFQ47220626-16524B11-F063-4DD5-968E-91A6684BC99CQ47825566-07F3926A-15E2-4F5D-AFE3-A2292E2DE134Q49334420-C5A3D97B-C911-4FAF-A7CC-B307436FBF04Q49400754-292E727E-546B-481E-B9E2-13E69A91EC09Q49496068-BD69DDC0-09D1-417D-9AEB-D3FE1C64F153Q49884762-C6BAA8DA-FFFE-404B-99B0-01A220F76A07Q50851021-C66208B1-6C4D-4279-9302-B7CBE707664CQ53421812-F5EDD09F-B9F7-46FA-9776-7728E1F3C5A3Q54969376-8A736BDC-F091-4F4C-9F30-485FDF339895Q55000578-601E2D71-6E55-4CAB-AD31-31F06E5C8523Q55353691-6731E239-4B08-4A50-AC67-FCC5FEEB7F30Q55427632-5F106C1B-8910-4E33-B29D-FA1F2F4D92F3Q57100494-5D0B7C02-7FEC-4D9C-83D1-8B2832FF71A4Q57106074-333B7CE7-F514-41AC-BAA1-199CE8D27D77
P2860
Past, present, and future challenges in breast cancer treatment.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Past, present, and future challenges in breast cancer treatment.
@en
type
label
Past, present, and future challenges in breast cancer treatment.
@en
prefLabel
Past, present, and future challenges in breast cancer treatment.
@en
P2093
P2860
P356
P1476
Past, present, and future challenges in breast cancer treatment.
@en
P2093
Eleftherios P Mamounas
Gabriel N Hortobagyi
George W Sledge
Harold J Burstein
P2860
P304
P356
10.1200/JCO.2014.55.4139
P407
P577
2014-06-02T00:00:00Z